Pharmaceutical
Biotechnology
Technology

Catalent

$40.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.27 (0.67%) Today
+$0.27 (0.67%) Today

Why Robinhood?

You can buy or sell Catalent and other stocks, options, ETFs, and crypto commission-free!

About

CATALENT, INC., also called Catalent, is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. Read More The Softgel Technologies segment focuses on the formulation, development, and manufacture of prescription and consumer health soft capsules, softgels, vegicaps and optishell capsules. The Biologics and Specialty Drug Delivery segment researches and develop biologic drug products in prefilled syringes, vials, cartridges, blow-fill-seal unit doses, and injectable formats. The Oral Drug Delivery segment offers formulates oral dosage forms. The Clinical Supply Services segment includes the packaging, labeling, storage, distribution, and inventory management of patient kits for clinical trials of drugs. It also provides clinical e-solutions and informatics, and global comparator sourcing services. The company was founded in April 2007 and is headquartered in Somerset, NJ.

Employees
10,700
Headquarters
Somerset, New Jersey
Founded
2007
Market Cap
5.89B
Price-Earnings Ratio
41.44
Dividend Yield
0.00
Average Volume
951.32K
High Today
$41.34
Low Today
$40.52
Open Price
$40.52
Volume
147.69K
52 Week High
$46.43
52 Week Low
$29.23

Collections

Pharmaceutical
Biotechnology
Technology
Health
Medical
Packaging
2014 IPO
US

News

TradingNewsNowMar 20

Recent Fundamentals: Catalent (NYSE: CTLT)

Catalent trades as part of the drug manufacturers industry and trades as part of the healthcare sector. The company CEO is John R. Chiminski. Catalent Inc is a drug development, delivery and supply partner company. It engages in advanced delivery technologies and development solutions for drugs, biologics, and consumer health products across US, Europe and other international markets. Previous Intraday Trading Performance: The CTLT stock showed a previous change of 0.24% with an open at 42.69 and a close ...

19
MarketBeatMar 16

Stock Price, News, & Analysis for Catalent

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary su...

2
Yahoo FinanceMar 15

CTLT or NBIX: Which Is the Better Value Stock Right Now?

CTLT vs. NBIX: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalent (CTLT) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores syst...

113

Earnings

$0.18
$0.34
$0.51
$0.67
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Apr 30, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.